Investigating the Gut Microbiota of Individuals With Adenoma, Advanced Adenoma and Colorectal Cancer
NCT ID: NCT07321548
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1757 participants
OBSERVATIONAL
2021-03-15
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal Immunochemical Test for Advanced Adenoma Detection in Colorectal Cancer Screening
NCT05200611
The Longterm Risk of Advanced Colorectal Neoplasia After Colonoscopy - A Population-based Cohort Study in Hong Kong
NCT04815525
External, Multicentre Validation of a Machine-Learning Model to Predict Colonic Adenoma in Indian Adults
NCT07329816
A Follow-up Colonoscopy Examination in Patients Who Had Previously Undergone Screening Colonoscopy
NCT00280332
Risk of Metachronous Advanced Colorectal Neoplastic Among Individuals With Varying Numbers of Non-Advanced Adenomas Detected During Screening Colonoscopy
NCT07302139
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Abnormality in the composition of the gut microbiota has been implicated as a potentially important etiological factor in the initiation and progression of CRC. With the widespread application of metagenomic analyses in the investigation of intestinal microbiota, an increasing number of bacteria have been identified to be positively associated with CRC. Recent basic research has established a critical function for the intestinal microbiota and specific bacterial species, in promoting colorectal tumorigenesis.
Based on the previously identified microbial markers, the investigators have recently proven that fecal microbial markers can also serve in non-invasive diagnosis of recurrent adenoma in post polypectomy patients. The results have shown that, the panel of microbial markers composing of Fusobacterium nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch), and the Lachnoclostridium marker m3 shows good diagnostic performance for colorectal adenoma and CRC. Microbial markers can be used to predict risk of adenoma recurrence during follow-up surveillance, with different scoring algorithms and cutoff values as compared to those used for colorectal neoplasm screening. However, only retrospective samples were used in the previous study, and sample size was limited. A prospective study is warranted to verify the accuracy of the microbial test for predicting recurrent adenoma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
N
Healthy control
Fecal immunochemical test
This diagnosis test is commonly used for screening CRC, which can act as an indicator to compare the performance of our new molecular test
nAA
Subject diagnosed with non-advanced adenoma
Fecal immunochemical test
This diagnosis test is commonly used for screening CRC, which can act as an indicator to compare the performance of our new molecular test
AA
Subject diagnosed with advanced adenoma
Fecal immunochemical test
This diagnosis test is commonly used for screening CRC, which can act as an indicator to compare the performance of our new molecular test
CRC
Subject diagnosed with colorectal cancer
Fecal immunochemical test
This diagnosis test is commonly used for screening CRC, which can act as an indicator to compare the performance of our new molecular test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fecal immunochemical test
This diagnosis test is commonly used for screening CRC, which can act as an indicator to compare the performance of our new molecular test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Will undergo a scheduled standard colonoscopy examination
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Gastroenterology and Hepatology, Vietnam
OTHER
Mahidol University
OTHER
National University of Malaysia
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jessie Qiaoyi Liang
Research Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prince of Wales Hospital
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CREC 2021.036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.